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Mutations in the retinoblastoma gene (RB-1) have ulation of E2F can be measured in tumors in vivo and
may be exploited to selectively drive gene expression inbeen described in a wide variety of neoplasms. Further-
more, many cancers that retain a wild-type RB-1 allele tumor cells.
pRB can both regulate the cell cycle and promoteharbor mutations that lead to the untimely phosphoryla-
tion and hence inactivation of the RB-1 gene product pRB. differentiation. We recently created pRB mutants that
cannot bind to E2F, cannot repress transcription, andExamples of such mutations include amplification of cyclin
D1, gain of function cdk4 missense mutations, and a homo- yet retain the ability to promote differentiation in model
systems. Interestingly, at least two naturally occurring,zygous deletion of the p16 cdk inhibitor. In summary,
inactivation of pRB may be a sine qua non of cancer. partially penetrant pRB also have this phenotype. In the
simplest view, the lower risk of retinoblastoma associ-How different cyclin-dependent kinases (CDKs) rec-
ognize substrates in general, and pRB, is largely un- ated with these mutants reflects the fact that they retain
a pRB tumor suppressor activity, namely, the ability toknown. We have identified a short, collinear peptide
sequence that serves as a cyclin/CDK2 substrate-recogni- promote differentiation. We are currently studying the
biochemical mechanisms underlying this pRB activity.tion motif. This sequence, as a synthetic peptide, will
specifically block the phosphorylation of pRB by cyclin/
CDK2 complexes. This peptide can be viewed as a lead REFERENCES
compound for the development of a small molecule 1. Sellers WR, Neumann E, Kaelin WG: The retinoblastoma protein
contains a potent transrepression domain which induces a cell-cycleCDK2 inhibitor. We are currently asking whether this
block when bound to DNA. Proc Natl Acad Sci USA 92:11544–paradigm can be extended to other CDKs such as CDK4.
11548, 1995
We and others have linked the ability of pRB to regu- 2. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin
late cell cycle progression to its ability to bind to mem- WG: Identification of a cyclin-cdk2 recognition motif present in
substrates and p21-like cdk inhibitors. Mol Cell Biol 16:6623–6633,bers of the E2F transcription factor family. pRB/E2F
1996complexes actively repress the transcription of E2F-re- 3. Kaelin WG: Alterations in G1/S cell-cycle control contributing to
sponsive genes. Thus, E2F responsive genes should be carcinogenesis. Ann NY Acad Sci 833:29–33, 1997
4. Sellers WR, Kaelin WG: Role of the retinoblastoma protein inmore actively transcribed in tumor cells than in normal
the pathogenesis of human cancer. J Clin Oncol 15:3301–3312, 1997cells because of the loss of pRB/E2F transcriptional re- 5. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG,
pressor complexes and liberation of free, transcription- Fine HA: Tumor-selective transgene expression in vivo mediated
by an E2F-responsive adenoviral vector. Nature Med 3:1145–1149,ally active E2F. To test this directly, we, in collaboration
1997with Dr. Howard Fine, constructed an adenoviral vector
6. Adams PD, Kaelin WG: Negative control elements of the cell cycle
in which a reporter gene was placed under E2F control. in human tumors. Curr Opin Cell Biol 10:791–797, 1998
7. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA,As expected, the infection of tumor cells in vivo with this
Kaye FJ, Lassar A, Kaelin WG: Stable binding to E2F is notvirus led to high levels of reporter activity. In contrast,
required for the retinoblastoma protein to activate transcription,
reporter activity was not measurable in surrounding nor- promote differentiation, and suppress tumor cell growth. Genes Dev
12:95–106, 1998mal cells despite evidence of viral infection. Thus, dereg-
